No data available for drug.
Dosing & Uses
Drug Interaction
Adverse Reaction
Actions and Spectrum
Black Box Warning
Contraindication / Caution
Pregnancy / Lactation
Pharmacology
Administration
Patient Information Leaflet
DRUG INTERACTION
No drug interaction found for ketoconazole and .
Contraindicated
almasilate
ketoconazole: they may diminish the serum concentration of antacids
calcium carbonate
ketoconazole: they may diminish the serum concentration of antacids
magaldrate
ketoconazole: they may diminish the serum concentration of antacids
nilotinib
when both drugs are combined, there may be an increased effect of nilotinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
sucralfate
Sucralfate may diminish the serum concentration of ketoconazole
rifabutin
rifabutin: they may diminish the serum concentration of ketoconazole
Serious Use Alternative
pemigatinib
It may enhance the effect when combined with pemigatinib by affecting CYP3A4 metabolism
alpelisib
when both drugs are combined, there may be a decreased metabolism of alpelisib
abemaciclib
when both drugs are combined, there may be a reduced metabolism of abemaciclib
erlotinib
when both drugs are combined, there may be a reduced metabolism of erlotinib
lorlatinib
the effect of ketoconazole is increased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
lapatinib
ketoconazole increases the effect of lapatinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
entrectinib
ketoconazole increases the effect of entrectinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
encorafenib
ketoconazole increases the effect of encorafenib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
midostaurin
ketoconazole increases the effect or level of midostaurin by altering the CYP3A4 enzyme metabolism
neratinib
ketoconazole increases the effect or level of midostaurin by altering the CYP3A4 enzyme metabolism
palbociclib
it increases the effect or level of palbociclib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
regorafenib
it will increase the impact or level of regorafenib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
ruxolitinib
it increases the effect or level of ruxolitinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
edoxaban
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
Monitor Closely
warfarin
This may increase the serum concentration when both drugs are combined
rilpivirine
it increases the concentration of rilpivirine in the serum
lumateperone
It may diminish the effect when combined with lumateperone by affecting CYP3A4 metabolism
cholic acid
It may enhance toxicity when combined with cholic acid by diminishing the elimination
amifampridine
it may enhance the risk of QTc prolongation when combined with amifampridine
ajmaline
when ajmaline is used together with ketoconazole, the risk or seriousness of QTc prolongation is enhanced
busulfan
increase the therapeutic effects of busulfan by inhibiting metabolism
paclitaxel
when both drugs are combined, there may be a decreased metabolism of paclitaxel
brentuximab
has a synergistic effect over brentuximab vedotin by showing altered intestinal/hepatic CYP3A4 enzyme metabolism.
daunorubicin
increase the therapeutic effect of daunorubicin by P-glycoprotein efflux transporter
gefitinib
ketoconazole increases the effect of gefitinib by altering the intestinal/ hepatic CYP3A4 enzyme metabolism
durvalumab
it may increase the hepatotoxic effects of ketoconazole
idarubicin
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporteridarub
finasteride
it increases the effect or level of finasteride by altering the intestinal/hepatic enzyme CYP3A4 metabolism
Minor
osimertinib
it increases the effect or level of osimertinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
sorafenib
it increases the efficacy of sorafenib by altering the hepatic CYP3A4 enzyme metabolism
doravirine
it increases by affecting the hepatic enzyme CYP3A4 metabolism
No data available for drug.
Dosing & Uses
Adult
Pediatric
Geriatric
Drug Interaction
DRUG INTERACTION
ketoconazole
&
No Drug Intearction Found. for ketoconazole and .
Contraindicated
almasilate
ketoconazole: they may diminish the serum concentration of antacids
calcium carbonate
ketoconazole: they may diminish the serum concentration of antacids
magaldrate
ketoconazole: they may diminish the serum concentration of antacids
nilotinib
when both drugs are combined, there may be an increased effect of nilotinib by affecting hepatic or intestinal enzyme cyp3a4 metabolism
sucralfate
Sucralfate may diminish the serum concentration of ketoconazole
rifabutin
rifabutin: they may diminish the serum concentration of ketoconazole
Serious Use Alternative
pemigatinib
It may enhance the effect when combined with pemigatinib by affecting CYP3A4 metabolism
alpelisib
when both drugs are combined, there may be a decreased metabolism of alpelisib
abemaciclib
when both drugs are combined, there may be a reduced metabolism of abemaciclib
erlotinib
when both drugs are combined, there may be a reduced metabolism of erlotinib
lorlatinib
the effect of ketoconazole is increased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
lapatinib
ketoconazole increases the effect of lapatinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
entrectinib
ketoconazole increases the effect of entrectinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
encorafenib
ketoconazole increases the effect of encorafenib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
midostaurin
ketoconazole increases the effect or level of midostaurin by altering the CYP3A4 enzyme metabolism
neratinib
ketoconazole increases the effect or level of midostaurin by altering the CYP3A4 enzyme metabolism
palbociclib
it increases the effect or level of palbociclib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
regorafenib
it will increase the impact or level of regorafenib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
ruxolitinib
it increases the effect or level of ruxolitinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
edoxaban
may increase the level of effectiveness through P-glycoprotein MDR1 efflux transporter
Monitor Closely
warfarin
This may increase the serum concentration when both drugs are combined
rilpivirine
it increases the concentration of rilpivirine in the serum
lumateperone
It may diminish the effect when combined with lumateperone by affecting CYP3A4 metabolism
cholic acid
It may enhance toxicity when combined with cholic acid by diminishing the elimination
amifampridine
it may enhance the risk of QTc prolongation when combined with amifampridine
ajmaline
when ajmaline is used together with ketoconazole, the risk or seriousness of QTc prolongation is enhanced
busulfan
increase the therapeutic effects of busulfan by inhibiting metabolism
paclitaxel
when both drugs are combined, there may be a decreased metabolism of paclitaxel
brentuximab
has a synergistic effect over brentuximab vedotin by showing altered intestinal/hepatic CYP3A4 enzyme metabolism.
daunorubicin
increase the therapeutic effect of daunorubicin by P-glycoprotein efflux transporter
gefitinib
ketoconazole increases the effect of gefitinib by altering the intestinal/ hepatic CYP3A4 enzyme metabolism
durvalumab
it may increase the hepatotoxic effects of ketoconazole
idarubicin
increase the therapeutic effect of idarubicin by P-glycoprotein efflux transporteridarub
finasteride
it increases the effect or level of finasteride by altering the intestinal/hepatic enzyme CYP3A4 metabolism
Minor
osimertinib
it increases the effect or level of osimertinib by altering the intestinal or hepatic CYP3A4 enzyme metabolism
sorafenib
it increases the efficacy of sorafenib by altering the hepatic CYP3A4 enzyme metabolism
doravirine
it increases by affecting the hepatic enzyme CYP3A4 metabolism
Actions and Spectrum
Adverse Reaction
Black Box Warning
Contraindication / Caution
Pregnancy / Lactation
Pharmacology
Administration
Patient Information Leaflet
medtigo
Action and Spectrum
Drug Interaction
Adverse Reaction
Black Box Warning
Contraindication / Caution
Pregnancy / Lactation
Pharmacology
Adminstartion
Patient Information Leaflet